CNC 225
Alternative Names: CNC-225Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Cancure
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Angiogenesis inhibitors; Galectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in Australia
- 11 Sep 2020 CNC 225 is available for licensing as of 11 Sep 2020. www.cancure.com
- 11 Sep 2020 Cancure has patent protection for CNC 225 in USA and Australia (Cancure website, September 2020)